Des/Stilboestrol Miss Emma Nicholson To ask the Secretary of State for Health (1) if he will meet the representatives of the DES/Stilboestrol Action Group in England;(2) if his Department plans to examine the conclusions of the DES/Stilboestrol symposium held in Dublin on 14 September;(3) if his Department will inquire into reports that the grandchildren of patients treated with the drug DES/Stilboestrol have suffered ill effects. Mrs. Virginia Bottomley The Committee on Safety of Medicines (CSM) carefully monitors all issues of drug safety. There is also a statutory obligation for pharmaceutical companies to provide details of any suspected adverse drug reactions which they may receive in relation to one of their products. Any new information relating to side effects from stilboestrol will be monitored in the usual way when it becomes available to the CSM. There are no plans to meet representatives of the DES Action Group.